PMID- 33294056
OWN - NLM
STAT- MEDLINE
DCOM- 20210819
LR  - 20210819
IS  - 1875-8630 (Electronic)
IS  - 0278-0240 (Print)
IS  - 0278-0240 (Linking)
VI  - 2020
DP  - 2020
TI  - Interleukin-18 Is a Prognostic Marker and Plays a Tumor Suppressive Role in Colon 
      Cancer.
PG  - 6439614
LID - 10.1155/2020/6439614 [doi]
LID - 6439614
AB  - Interleukin-18 (IL-18) belongs to the IL-1 family and is an essential 
      proinflammatory and immune regulatory cytokine. The present study was designed to 
      investigate the expression and function of IL-18 in colon cancer. In clinical 
      analyses, mRNA and protein expressions of IL-18 were decreased in tissues of 
      colon cancer patients. This decreased expression of IL-18 was significantly 
      correlated with the tumor size (P = 0.001) and American Joint Committee on Cancer 
      (AJCC) stage (P = 0.013). Patients with IL-18-positive tumors had a better 
      survival rate than patients with IL-18-negative tumors. Moreover, upregulation of 
      IL-18 inhibited colon cancer cell proliferation. Our data suggest that the 
      decreased expression of IL-18 in colon cancer was associated with prognosis and 
      tumor proliferation. IL-18 may be considered a novel tumor suppressor and a 
      potential therapeutic target for colon cancer patients.
CI  - Copyright (c) 2020 Xiaodong Feng et al.
FAU - Feng, Xiaodong
AU  - Feng X
AUID- ORCID: 0000-0003-2700-8304
AD  - Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao 266000, China.
FAU - Zhang, Zhijun
AU  - Zhang Z
AD  - Department of Clinical Laboratory, Taian City Central Hospital, Taian 271000, 
      China.
FAU - Sun, Peng
AU  - Sun P
AD  - Department of Pathology, Taian City Central Hospital, Taian 271000, China.
FAU - Song, Guanghui
AU  - Song G
AD  - Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao 266000, China.
FAU - Wang, Lu
AU  - Wang L
AD  - Department of Education and Training, The Affiliated Hospital of Qingdao 
      University, Qingdao University, Qingdao 266000, China.
FAU - Sun, Zhenqing
AU  - Sun Z
AD  - Department of General Surgery, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao 266000, China.
FAU - Yuan, Ning
AU  - Yuan N
AD  - Department of Clinical Laboratory, The Seventh Medical Center of PLA General 
      Hospital, Bejing 100010, China.
FAU - Wang, Qing
AU  - Wang Q
AD  - Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao 266000, China.
FAU - Lun, Limin
AU  - Lun L
AUID- ORCID: 0000-0001-9543-3789
AD  - Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao 266000, China.
LA  - eng
PT  - Journal Article
DEP - 20201126
PL  - United States
TA  - Dis Markers
JT  - Disease markers
JID - 8604127
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (IL18 protein, human)
RN  - 0 (Interleukin-18)
SB  - IM
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Colonic Neoplasms/genetics/metabolism/mortality/*pathology
MH  - Databases, Genetic
MH  - *Down-Regulation
MH  - Female
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Interleukin-18/*genetics/*metabolism
MH  - Male
MH  - Neoplasm Staging
MH  - Survival Analysis
MH  - Tumor Burden
PMC - PMC7714607
COIS- The authors declare that they have no conflict of interest.
EDAT- 2020/12/10 06:00
MHDA- 2021/08/20 06:00
PMCR- 2020/11/26
CRDT- 2020/12/09 06:13
PHST- 2019/11/20 00:00 [received]
PHST- 2020/09/17 00:00 [revised]
PHST- 2020/11/11 00:00 [accepted]
PHST- 2020/12/09 06:13 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2021/08/20 06:00 [medline]
PHST- 2020/11/26 00:00 [pmc-release]
AID - 10.1155/2020/6439614 [doi]
PST - epublish
SO  - Dis Markers. 2020 Nov 26;2020:6439614. doi: 10.1155/2020/6439614. eCollection 
      2020.